S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
NASDAQ:FONR

FONAR (FONR) Stock Forecast, Price & News

$17.66
-0.10 (-0.56%)
(As of 06/9/2023 ET)
Compare
Today's Range
$17.50
$17.80
50-Day Range
$15.27
$17.76
52-Week Range
$13.28
$19.00
Volume
6,711 shs
Average Volume
9,346 shs
Market Capitalization
$115.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

FONR stock logo

About FONAR (NASDAQ:FONR) Stock

FONAR Corp. engages in the design, manufacture, sale, and servicing of magnetic resonance imaging scanners. It operates through the Manufacturing and Servicing of Medical Equipment and Management of Diagnostic Imaging Center segments. The Manufacturing and Servicing of Medical Equipment segment promotes its product, Fonar Upright MRI. The Management of Diagnostic Imaging Center segment offers management, administrative, billing and collection services, office space, equipment, repair, maintenance service and clerical, and non-medical personnel to medical providers through its subsidiary, Health Management Corp. of America. The company was founded by Raymond V. Damadian on July 17, 1978 and is headquartered in Melville, NY.

Receive FONR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FONAR and its competitors with MarketBeat's FREE daily newsletter.

FONR Stock News Headlines

Analyzing Positron (OTCMKTS:POSC) and FONAR (NASDAQ:FONR)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
FONAR (NASDAQ:FONR) Lifted to "Strong-Buy" at StockNews.com
StockNews.com Downgrades FONAR (NASDAQ:FONR) to Buy
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
FONAR Reports First Quarter 2023 Earnings
Fonar Corporation Common Stock (FONR)
See More Headlines

FONR Price History

FONR Company Calendar

Last Earnings
5/11/2020
Today
6/10/2023
Fiscal Year End
6/30/2023
Next Earnings (Estimated)
8/21/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FONR
Employees
495
Year Founded
N/A

Profitability

Net Income
$12.44 million
Pretax Margin
17.11%

Debt

Sales & Book Value

Annual Sales
$97.59 million
Cash Flow
$3.91 per share
Book Value
$22.31 per share

Miscellaneous

Free Float
5,977,000
Market Cap
$115.50 million
Optionable
Not Optionable
Beta
0.91

Key Executives

  • Timothy R. Damadian
    Chairman, President & Chief Executive Officer
  • Luciano Bonanni
    Chief Operating Officer & Executive Vice President
  • Claudette J. V. Chan
    Secretary & Director
  • Daniel Culver
    Communications Director













FONR Stock - Frequently Asked Questions

How have FONR shares performed in 2023?

FONAR's stock was trading at $16.75 at the beginning of 2023. Since then, FONR shares have increased by 5.4% and is now trading at $17.66.
View the best growth stocks for 2023 here
.

When is FONAR's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our FONR earnings forecast
.

How were FONAR's earnings last quarter?

FONAR Co. (NASDAQ:FONR) posted its earnings results on Monday, May, 11th. The medical equipment provider reported $0.18 earnings per share for the quarter. The medical equipment provider earned $21.69 million during the quarter. FONAR had a net margin of 10.63% and a trailing twelve-month return on equity of 7.97%.

What other stocks do shareholders of FONAR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FONAR investors own include Gilead Sciences (GILD), Amarin (AMRN), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Pfizer (PFE), Bausch Health Companies (BHC), Incyte (INCY), Jazz Pharmaceuticals (JAZZ), Lannett (LCI) and Madrigal Pharmaceuticals (MDGL).

What is FONAR's stock symbol?

FONAR trades on the NASDAQ under the ticker symbol "FONR."

Who are FONAR's major shareholders?

FONAR's stock is owned by many different retail and institutional investors. Top institutional investors include Kayne Anderson Rudnick Investment Management LLC (9.69%), Dimensional Fund Advisors LP (6.24%), Renaissance Technologies LLC (5.03%), Money Concepts Capital Corp (4.63%), LSV Asset Management (2.24%) and BlackRock Inc. (1.51%). Insiders that own company stock include Luciano B Bonanni and Timothy Raymond Damadian.
View institutional ownership trends
.

How do I buy shares of FONAR?

Shares of FONR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FONAR's stock price today?

One share of FONR stock can currently be purchased for approximately $17.66.

How much money does FONAR make?

FONAR (NASDAQ:FONR) has a market capitalization of $115.50 million and generates $97.59 million in revenue each year.

How many employees does FONAR have?

The company employs 495 workers across the globe.

How can I contact FONAR?

FONAR's mailing address is 110 Marcus Drive, Melville NY, 11747. The official website for the company is www.fonar.com. The medical equipment provider can be reached via phone at (631) 694-2929, via email at investor@fonar.com, or via fax at 631-753-5150.

This page (NASDAQ:FONR) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -